Physician profile
Meredith L Moore
NPI 1578559415
$11,614.72
in general payments reported to CMS, 2019-2025
32 companies · $2,890 in 2025
The $2,890 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $896 · 2021: $1,191 · 2022: $1,979 · 2023: $2,072 · 2024: $1,912 · 2025: $2,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,654 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,653.96 |
| Education | $219.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,329.53 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,659.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $967.56 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Csl Behring | $913.58 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Glaxosmithkline, LLC. | $869.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $843.71 | 2019-2025 | Xolair |
| Amgen INC. | $707.24 | 2021-2025 | Tezspire |
| Pfizer INC. | $459.90 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $321.21 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $319.83 | 2021-2025 | Ruconest, Joenja |
| Regeneron Healthcare Solutions, INC. | $278.21 | 2019-2025 | Dupixent |
| Optinose US, INC. | $273.01 | 2020-2025 | |
| Grifols USA, LLC | $251.24 | 2020-2025 | Xembify |
| Alk-Abello, INC | $214.12 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Novartis Pharmaceuticals Corporation | $202.13 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $173.24 | 2023-2025 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $151.99 | 2023-2025 | |
| Kaleo, INC. | $126.57 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $118.78 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $77.62 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $73.52 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $60.33 | 2025 | Sajazir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.12 | 2020-2022 | |
| Ionis Pharmaceuticals, INC. | $39.77 | 2025 | Dawnzera |
| Gc Biopharma USA, INC. | $23.09 | 2025 | Alyglo |
| Galderma Laboratories, L.P. | $17.88 | 2025 | Nemluvio |
| Bio Products Laboratory USA, INC. | $17.24 | 2020 | |
| Circassia INC. | $16.38 | 2019 | |
| Horizon Therapeutics Plc | $16.15 | 2021 | |
| Seqirus USA INC | $16.08 | 2023 | Flucelvax Quadrivalent |
| Incyte Corporation | $14.69 | 2021 | |
| Octapharma USA, INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.